MetaVia

MetaVia Deferred Tax Liabilities

Deferred Tax Liabilities of MetaVia (MTVA) as of Oct 17, 2026.

Deferred Tax Liabilities

-USD

Last updated:

Deferred Tax Liabilities of MetaVia is 2026 - USD. Deferred Tax Liabilities of MetaVia was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? MetaVia Inc, based in Boston, US, operates in the Health Care sector as a biotechnology company. It develops pharmaceuticals for neurodegenerative disorders, focusing on Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The company’s product candidates include NB-01 for neuropathic pain, NB-02 for Alzheimer’s and tauopathies, and Gemcabene for dyslipidemia-related conditions. MetaVia went public on 5 August 2016 with a small team of nine employees. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities MetaVia since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's MetaVia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MetaVia

All Key Metrics — MetaVia